ADRX is a drug discovery platform that transforms atomic structures into small molecule therapies. Using proprietary structure-based technology, they are developing small molecule disaggregators and inhibitors that target previously unreachable misfolded proteins in neurodegenerative diseases. Tau, TDP-43, and alpha-synuclein programs are in its